Within-patient comparison between [<sup>68</sup>Ga]Ga-tilmanocept PET/CT lymphoscintigraphy and [<sup>99m</sup>Tc]Tc-tilmanocept lymphoscintigraphy for sentinel lymph node detection in oral cancer: a pilot study.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 34962582.
- Also identified by DOI 10.1007/s00259-021-05645-0.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To compare sentinel lymph node (SLN) identification using [<sup>68</sup>Ga]Ga-tilmanocept PET/CT lymphoscintigraphy to [<sup>99m</sup>Tc]Tc-tilmanocept lymphoscintigraphy (including SPECT/CT) in early-stage oral cancer. Furthermore, to assess whether reliable intraoperative SLN localization can be performed with a conventional portable gamma-probe using [<sup>99m</sup>Tc]Tc-tilmanocept without the interference of [<sup>68</sup>Ga]Ga-tilmanocept in these patients. This prospective within-patient comparison pilot study evaluated SLN identification by [<sup>68</sup>Ga]Ga-tilmanocept PET/CT lymphoscintigraphy compared to conventional lymphoscintigraphy using [<sup>99m</sup>Tc]Tc-tilmanocept (~ 74 MBq) in 10 early-stage oral cancer patients scheduled for SLN biopsy. After conventional [<sup>99m</sup>Tc]Tc-tilmanocept lymphoscintigraphy, patients underwent peritumoral administration of [<sup>68</sup>Ga]Ga-tilmanocept (~ 10 MBq) followed by PET/CT acquisition initiated 15 min after injection. Intraoperative SLN localization was performed under conventional portable gamma-probe guidance the next day; the location of harvested SLNs was correlated to both lymphoscintigraphic images in each patient. A total of 24 SLNs were identified by [<sup>99m</sup>Tc]Tc-tilmanocept lymphoscintigraphy, all except one were also identified by [<sup>68</sup>Ga]Ga-tilmanocept PET/CT lymphoscintigraphy. [<sup>68</sup>Ga]Ga-tilmanocept PET/CT lymphoscintigraphy identified 4 additional SLNs near the injection site, of which two harbored metastases. Lymphatic vessels transporting [<sup>68</sup>Ga]Ga-tilmanocept were identified by PET/CT lymphoscintigraphy in 80% of patients, while draining lymphatic vessels were visualized by [<sup>99m</sup>Tc]Tc-tilmanocept lymphoscintigraphy in 20% of patients. Of the 33 SLNs identified by [<sup>68</sup>Ga]Ga-tilmanocept PET/CT lymphoscintigraphy, 30 (91%) were intraoperatively localized under conventional gamma-probe guidance. [<sup>68</sup>Ga]Ga-tilmanocept PET/CT lymphoscintigraphy provided more accurate identification of SLNs and improved visualization of lymphatic vessels compared to [<sup>99m</sup>Tc]Tc-tilmanocept lymphoscintigraphy. When combined with peritumoral administration of [<sup>99m</sup>Tc]Tc-tilmanocept, SLNs detected by [<sup>68</sup>Ga]Ga-tilmanocept PET/CT lymphoscintigraphy can be reliably localized during surgery under conventional gamma-probe guidance.
Medical subject headings
- Mouth Neoplasms
- Sentinel Lymph Node